ReviewAllergy2022
Cannabis-related allergies: An international overview and consensus recommendations.
Review in Allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 64 citations in OpenAlex.
- Review
- Lipid Transfer Protein Allergens: A Comprehensive Overview of Current Knowledge.International journal of molecular sciences · 2026Review
- Temporal changes in allergen-specific IgE sensitization patterns in Xiamen, 2019-2023: a retrospective cross-sectional analysis.Frontiers in public health · 2026Article
- Work-Related Asthma in the Cannabis Industry: Findings From California, Massachusetts, Michigan, and Washington.Journal of occupational and environmental medicine · 2025Article
- The Associative Impact of Recreational Cannabis Use on Sinonasal Diseases.Laryngoscope investigative otolaryngology · 2025Article
- Cannabis and Dermatological Implications: A Traditional Review of Adverse Cutaneous Reactions and Systemic Risks.Cureus · 2025Review
- IgE-mediated lipid transfer protein allergy in children.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Review
- IgE-Mediated Cannabis Allergy and Cross-Reactivity Syndromes: A Roadmap for Correct Diagnosis and Management.Current allergy and asthma reports · 2024Review
- Bioaerosol Exposures and Respiratory Diseases in Cannabis Workers.Current allergy and asthma reports · 2024Review
- IgE-Mediated Allergy and Asymptomatic Sensitization to Cannabis Allergens-Review of Current Knowledge and Presentation of Six Cases.Medicina (Kaunas, Lithuania) · 2024Review
- Imported allergens in Italy: an emerging issue.Italian journal of pediatrics · 2024Review
- Feast for thought: A comprehensive review of food allergy 2021-2023.The Journal of allergy and clinical immunology · 2024Review
- Concerns Related to the Consequences of Pediatric Cannabis Use: A 360-Degree View.Children (Basel, Switzerland) · 2023Review
- Relevance of lipid transfer protein to Cannabis sensitization in North America.The journal of allergy and clinical immunology. In practice · 2023Article
- Epicutaneous Sensitization to the Phytocannabinoid β-Caryophyllene Induces Pruritic Inflammation.International journal of molecular sciences · 2023Article
- Proteomics-Based Approach for Detailing the Allergenic Profile of Cannabis Chemotypes.International journal of molecular sciences · 2023Article
- The Emerging Spectrum of Respiratory Diseases in the U.S. Cannabis Industry.Seminars in respiratory and critical care medicine · 2023Article
- A review of cannabis allergy in the early days of legalization.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- Immunomodulatory Actions of Cannabinoids: Clinical Correlates and Therapeutic Opportunities for Allergic Inflammation.The journal of allergy and clinical immunology. In practice · 2023Review
- Vegan diets from an allergy point of view - Position paper of the DGAKI working group on food allergy.Allergologie select · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 18 institutions in 6 countries.
Funding
Abstract
Cannabis is the most widely used recreational drug in the world. Cannabis sativa and Cannabis indica have been selectively bred to develop their psychoactive properties. The increasing use in many countries has been accelerated by the COVID-19 pandemic. Cannabis can provoke both type 1 and type 4 allergic reactions. Officially recognized allergens include a pathogenesis-related class 10 allergen, profilin, and a nonspecific lipid transfer protein. Other allergens may also be relevant, and recognition of allergens may vary between countries and continents. Cannabis also has the potential to provoke allergic cross-reactions to plant foods. Since cannabis is an illegal substance in many countries, research has been hampered, leading to challenges in diagnosis since no commercial extracts are available for testing. Even in countries such as Canada, where cannabis is legalized, diagnosis may rely solely on the purchase of cannabis for prick-to-prick skin tests. Management consists of avoidance, with legal issues hindering the development of other treatments such as immunotherapy. Education of healthcare professionals is similarly lacking. This review aimed to summarize the current status of cannabis allergy and proposes recommendations for the future management of this global issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.